Selank vs Semax

Selank

Selank is a synthetic heptapeptide analogue of the naturally occurring immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with a Pro-Gly-Pro sequence for enhanced metabolic stability. Selank exerts its effects primarily through modulation of the GABAergic system, influencing GABA-A receptor subunit expression and monoamine neurotransmitter metabolism, particularly serotonin and norepinephrine. It also demonstrates immunomodulatory activity by regulating cytokine balance and enhancing phagocytic activity. Research conducted at the Institute of Molecular Genetics in Moscow revealed that Selank significantly altered the expression of 36 genes related to GABAergic neurotransmission in hippocampal tissue (Zozulya et al., 2001). Studies in Bulletin of Experimental Biology and Medicine demonstrated anxiolytic effects comparable to benzodiazepines but without sedation, motor impairment, or dependence risk. Further work by Kozlovskii and Danchev showed that Selank enhanced memory trace stability in rodent avoidance tasks, suggesting dual anxiolytic-nootropic activity. Compared to Semax, Selank produces a calming, anxiolytic profile rather than a stimulatory cognitive boost. Where Semax primarily modulates BDNF and melanocortin pathways, Selank operates through GABA modulation and immune regulation. Diazepam and other classical anxiolytics share Selank's target system but carry tolerance and withdrawal risks that research suggests Selank does not. Store lyophilized Selank at -20°C in a desiccated environment. After reconstitution with bacteriostatic water, refrigerate at 2-8°C and use within 3-4 weeks. Selank is primarily studied by neuropharmacologists, behavioral researchers investigating anxiety models, and immunologists examining peptide-based immune modulation.

Semax

Semax is a synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10), with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Unlike native ACTH, Semax has been structurally modified to eliminate hormonal activity while retaining and enhancing nootropic and neuroprotective properties. It acts primarily by upregulating brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression, supporting neuronal survival and synaptic plasticity. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax has been the subject of extensive research. Studies published in Doklady Biological Sciences demonstrated that Semax increased BDNF mRNA expression by up to 1.4-fold in the hippocampus and frontal cortex of rodent models. Research by Ashmarin et al. showed cognitive improvements in attention, memory consolidation, and learning tasks. Clinical investigations in stroke models indicated that Semax administration within 6 hours of ischemic events was associated with improved neurological outcomes and reduced infarct progression. Compared to Selank, another Russian-developed nootropic peptide, Semax is more stimulatory and primarily targets cognitive performance and neuroprotection, while Selank leans toward anxiolytic and immunomodulatory effects. Both share favorable safety profiles in preclinical research, but their mechanisms diverge -- Semax through melanocortin pathways and Selank through tuftsin-based immunomodulation. Lyophilized Semax should be stored at -20°C and protected from light. Reconstitute with bacteriostatic water and store at 2-8°C, using within 3-4 weeks. Semax is actively researched by neuroscientists, cognitive psychologists, and stroke researchers investigating neuroprotective interventions.

Frequently Asked Questions